News News Details

中国药促会、倚锋创投与招商局集团将以建立基金会和产业基金形式共同推动国内创新医药发展

Date: 2018-03-22
Views: 24

2018年3月21日上午,中国医药创新促进会(简称“中国药促会”)执行会长宋瑞霖、深圳倚锋创业投资有限公司董事长朱晋桥、武汉禾元生物生物董事长杨代常等一行人到访香港招商局集团(简称“招商局”)总部,受到招商局集团健康产业事业部部长余世新一行全程接待。


中国药促会、倚锋创投与招商局集团将以建立基金会和产业基金形式共同推动国内创新医药发展


会议交流


会议上,余世新部长介绍了招商局拓展大健康板块布局医药健康领域投资的战略规划,表示招商局将发挥自身已有金融、医疗、保险、地产等优势在医养结合、药品医疗器械、医院等方面进行战略布局,为中国大健康产业作出应有的贡献。

宋瑞霖会长表示,创新驱动已经成为我国经济发展的战略方向,国家近期出台的一系列有关医药改革政策以及香港交易所引进针对生物科技公司零利润IPO政策,掀起了医药创新与投资大潮,招商局作为我国最具历史的国有企业,应当在医药创新领域发挥重要作用。



中国药促会、倚锋创投与招商局集团将以建立基金会和产业基金形式共同推动国内创新医药发展


签订合作备忘录


会议就中国医药产业现状、及招商局集团布局大健康板块等内容进行了深入的探讨,并表示未来将根据自身优势开展紧密的合作,发挥各自优势,在产业政策研究、行业趋势分析、医药创新研发、专家资源支持等多方面探索合作模式,明确通过共同以建立基金会和产业基金的形式支持中国医药创新。并共同努力,使招商局成为中国医药创新骨干力量。会谈结束后中国药促会秘书长冯岚、招商局集团健康产业事业部运营总监徐海英代表会谈双方签订了合作备忘录。


中国药促会、倚锋创投与招商局集团将以建立基金会和产业基金形式共同推动国内创新医药发展



会后合影


同行成员还包括深圳奥萨医药董事长徐希平、四川九章生物董事长张洁、海捷投资控股集团首席合伙人储慧斌、上海醴泽投资管理合伙人张勇。


Related News / Recommended news More
2022 - 08 - 10
On August 9, the National Health Commission issued a notice, according to the approval opinions of the State Food and Drug Administration on the application for registration of additional indications for the treatment of novel coronavirus pneumonia with azvudine tablets. In order to further improve the antiviral treatment scheme for novel coronavirus pneumonia, the drug was included in the diagnos...
2022 - 08 - 05
Just recently, the Hong Kong Stock Exchange welcomed the successful submission of the first share of the new crown oral drug. On August 4, the Hong Kong Stock Exchange disclosed that Henan Zhenzhen Biotechnology Co., Ltd. (hereinafter referred to as 'Genuine Biotech') submitted a listing application to the Hong Kong Stock Exchange. Efung Capital is the only investment institution...
2022 - 08 - 01
Recently, Apexigen, a portfolio company of Efung Capital, and Brookline Capital Acquisition Corp.-a Special Purpose Acquisition Company (SPAC)-entered an official merger process, resulting that Brookline Capital Acquisition Corp. was renamed to Apexigen, Inc. Guided and led by Dr. Xiaodong Yang, president as well as Chief Executive Officer (CEO) of Apexigen company, the firm joined the listing of ...
2022 - 07 - 25
On July 25, 2022, the State Drug Administration proclaimed that, in accordance with the relevant provisions of the Drug Administration Law and specific drug approval procedures, the State Drug Administration conducted emergency review and approved Henan Zhenzhen Biotechnology Co., Ltd. with certain conditions. The registration application for Azvudine tablets to treat the novel coronavirus pneumon...
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务